Effect of Chitosan oligosaccharides on ischemic symptom and gut microbiota disbalance in mice with hindlimb ischemia. (15th July 2020)

• Record Type: Journal Article
• Authors: Zhu, Lin; Hu, Baifei; Guo, Yanlei; Yang, Huabing; Zheng, Junping; Yao, Xiaowei; Hu, Haiming; Liu, Hongtao
• Is Part Of: Carbohydrate polymers. Volume 240(2020)
• Publication Date: 2020-07-15
• Subjects: COS Chitosan oligosaccharides -- H&E Hematoxylin and Eosin -- KEGG Keyoto Encyclopedia of Genes and Genomes -- OTU Operational Taxonomic Unit -- PICRUSt Phylogenetic Investigation of Communities by Reconstruction of Unobserved States -- QIIME Quantitative Insights Into Microbial Ecology -- qRT-PCR quantitative real-time PCR -- TNF-α tumor necrosis factor alpha -- IL-1β interleukin-1β -- IL-6 interleukin-6 -- IL-8 interleukin-8 -- HO-1 heme oxygenase 1 -- NQO1 NAD(P)H quinone dehydrogenase 1 -- CSF colony stimulating factor -- COX-5b cytochrome oxidase assembly protein 5b -- VEGF vascular endothelial growth factor; Lower limb ischemia -- Chitosan oligosaccharides -- gut microbiota -- metabolomics -- inflammation -- oxidative stress; Polysaccharides -- Periodicals; Polysaccharides -- Periodicals; Polysaccharides -- Périodiques; Electronic journals; 547.78
• DOI: 10.1016/j.carbpol.2020.116271
• Languages: English
• ISSNs: 0144-8617

Abstract

Highlights: COS promoted the blood perfusion and neovascularization in hindlimb ischemia of mice. COS suppressed inflammation and oxidative stress in ischemic hindlimb. COS improved disbalance of gut microbiota community induced by ischemia. COS affected the metabolomics in plasma of mice with hindlimb ischemia. Abstract: This study was designed to explore the effect of Chitosan oligosaccharides (COS) on mouse hindlimb ischemia by femoral artery ligation. Here, we demonstrated that COS treatment statistically promoted the blood perfusion and neovascularization in ischemic hindlimb of mice, accompanied by the suppression of inflammation and oxidative stress. By 16S rDNA gene sequencing, the disbalanced gut microbiota was observed in ischemic mice, while COS treatment, at least in part, restored the abundance changes of some intestinal bacteria at either phylum or genus levels. Based on metabolomics analysis on mouse plasma by UPLC-QTOF-MS, we screened 20 metabolites with the largest responses to ischemia, several of which were markedly reversed by COS. By Spearman's correlation analysis, the changed metabolites might act as a bridge between improved intestinal bacterial structure and alleviated hindlimb ischemia of mice treated by COS. Our studies point towards a potential role of COS in treatment of peripheral ischemia diseases.